Dr Philippe Rogueda
Co-Founder & Chief Business Officer

Is this your profile?

About

Philippe Rogueda, PhD, co-founded Merxin Ltd in 2015 and currently serves as Chief Business Officer. His expertise spans across multiple facets of the inhalation field, particularly with dry powder and SMIs. Dr Rogueda’s
passion lies in the development of SMI technology, particularly for biologics, which he believes holds immense potential to revolutionise the delivery of inhaled therapies.

With over a decade of experience in the inhalation sector, Dr Rogueda’s deep knowledge and innovative approach to inhalation technologies make him a key figure in advancing medical device development for improved drug delivery systems.

Contributions

TRANSFORMING MENTAL HEALTHCARE: THE RISE OF INHALABLE PSYCHEDELICS?

Philippe Rogueda discusses how inhaled psychedelic therapies are emerging as a potential game-changer in mental health due to their fast onset and precise dosing, and how their potential has resulted in a growing pipeline of therapies, paving the way for a new era in mental healthcare.

More contributions

SOFT MIST INHALERS VERSUS NEBULISERS: DELIVERY EQUIVALENCE & FUTURE THERAPIES

Zaid Aqrawe, Philippe Rogueda, Darragh Murnane and Bryan Eng, discuss the opportunity presented by soft mist inhalers as an alternative delivery device to nebulisers for inhaled therapies, contrasting the two device categories across multiple factors.

DELIVERING BIOLOGICS WITH SOFT MIST INHALERS – A MARKET POISED TO EXPAND

Philippe Rogueda discusses the inhalable biologics market, how the introduction of soft mist inhalers represents a significant opportunity for new and old therapeutics alike, and how the market is poised for a major expansion in therapeutic application, size and value.

OFF-THE-SHELF OR CUSTOM-MADE? CHOOSING A DRY POWDER INHALER

Philippe Rogueda discusses the manifold factors that need to be taken into account when choosing a dry powder inhaler – beyond just the target disease, formulation and patient population.

PUBLIC INTEREST & INCENTIVES FOR INNOVATORS OF INHALED PRODUCTS

Igor Gonda, David Cipolla and Philippe Rogueda discuss the changes needed to increase the number of approved generic orally inhaled drug products (OIDPs) whilst providing additional incentives to innovators to meet the needs of the general public.

Top